Entries by Roger Tatoud

IAS 2019: Promising HIV Vaccine Study Results Point to the Need to Intensify and Accelerate Preparation for Future Research and Access Challenges

July 23, 2019 in /by

The Global HIV Vaccine Enterprise welcomes the important and encouraging results of the ASCENT study and new clinical data from the APPROACH study presented at the 10th IAS Conference on HIV Science (IAS 2019), held in Mexico City, Mexico. These two studies build on the success of previous research using mosaic-based vaccines and provide important data to inform ongoing efforts to develop an effective, implementable vaccine regimen – a central part of a comprehensive, global HIV prevention strategy.

New home for a renewed Enterprise

July 15, 2019 in /by

The HIV vaccine field has built considerable momentum in recent times with multiple efficacy-stage programmes underway and new vaccine concepts in the clinical pipeline. The range of opportunities and possibilities is matched by a shared understanding and sense of urgency that the field is underprepared for the range of complex challenges that remain.

HIV Vaccine R&D at the IAS Science Conference 2019

July 15, 2019 in /by

The IAS Conference on HIV Science is the world’s most influential meeting on HIV research and its applications. This biennial conference presents the critical advances in basic, clinical and operational research that moves science into policy and practice. Through its open and inclusive programme development, the meeting sets the gold standard of HIV research featuring highly diverse and cutting-edge studies.

HIV Vaccine research and development will be very much featured before and during the conference.